Prothena Announces Appointment of Chief Legal Officer
DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery,
development and commercialization of novel antibodies for the potential
treatment of diseases that involve protein misfolding or cell adhesion,
announced today the appointment of Arthur W. ("Bill") Homan as Chief Legal
Officer.
"Bill has broad legal experience with publicly-traded, development and
commercial-stage life science companies," said Dr. Dale Schenk, President and
Chief Executive Officer of Prothena. "In particular, his background in managing
corporate governance and compliance programs, supporting operational teams, and
advising on various business transactions will strengthen our management team as
we continue to target proteins in novel ways to resolve unmet clinical needs in
patients."
Prior to joining Prothena, Mr. Homan was Senior Vice President, General Counsel
and Secretary at Complete Genomics, Inc., a life sciences company, until its
sale in 2013. Previously, Mr. Homan was Senior Vice President, General Counsel
and Secretary of Varian, Inc., a life science instruments company, from 1999
until its acquisition in 2010 by Agilent Technologies, Inc. Prior to that, he
served at Varian Associates, Inc. as Associate General Counsel, and at a San
Francisco law firm. Mr. Homan received a B.A. in Economics and Political Science
from Virginia Polytechnic Institute and State University, and a J.D. from the
University of Virginia.
About Prothena
Prothena Corporation plc is a clinical stage biotechnology company focused on
the discovery, development and commercialization of novel antibodies for the
potential treatment of diseases that involve protein misfolding or cell
adhesion. These potential therapies have a number of indications, including AL
and AA forms of amyloidosis (NEOD001), Parkinson's disease and related
synucleinopathies (PRX002), and novel cell adhesion targets involved in
inflammatory diseases and metastatic cancers (PRX003). For more information,
please visit www.prothena.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements relate to, among other things, our
expectations regarding our Chief Legal Officer's contributions to Prothena.
These forward-looking statements are identified by their use of terms and
phrases such as "anticipate," "believe," "could," "should," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "potential," "target,"
"will" and similar terms and phrases, including references to assumptions. These
statements are based on assumptions that may not prove accurate. Actual results
could differ materially from those anticipated due to known and unknown risks,
uncertainties and other factors including, but not limited to the risks and
uncertainties described in the "Risk Factors" section of Prothena's Annual
Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on
March 7, 2014, and the "Risk Factors" section of our and Quarterly Reports on
Form 10-Q filed with the SEC from time to time. Prothena undertakes no
obligation to update publicly any forward-looking statements contained in this
press release as a result of new information, future events or changes in
Prothena's expectations.
CONTACT: Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com
Media: Anita Kawatra
646-256-5116, anita.kawatra@prothena.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Prothena Corporation via GlobeNewswire
[HUG#1780248]